Journal of the Korean Society of Radiology (대한영상의학회지)

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Update in Diagnosis of Idiopathic Pulmonary Fibrosis and Interstitial Lung Abnormality

특발폐섬유증 진단의 최신 지견과 간질성폐이상

  • Bo Da Nam (Department of Radiology, Soonchunhyang University Seoul Hospital) ;
  • Jung Hwa Hwang (Department of Radiology, Soonchunhyang University Seoul Hospital)
  • 남보다 (순천향대학교 서울병원 영상의학과) ;
  • 황정화 (순천향대학교 서울병원 영상의학과)
  • Received : 2021.04.28
  • Accepted : 2021.06.06
  • Published : 2021.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Idiopathic pulmonary fibrosis (IPF), based on the 2018 international clinical practice guidelines, can be diagnosed with a usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) and compatible clinical findings. Given that imaging is pivotal for IPF evaluation and diagnosis, more emphasis should be placed on the integration of clinical, radiological, and pathologic findings for multidisciplinary diagnosis. Interstitial lung abnormality (ILA), on the other hand, has a purely radiological definition based on the incidental identification of CT abnormalities. Taken together, differentiation between ILA and clinically significant interstitial lung disease (ILD) must be based on proper clinical evaluation. With this review, the recent updates in IPF diagnosis and the radiologic considerations for ILA can be well understood, which can be helpful for the proper diagnosis and management of patients with diffuse interstitial pulmonary fibrosis.

최신 국제 임상진료지침을 기반으로 한 특발폐섬유증의 진단은 부합하는 임상 소견과 함께 고해상 CT에서 전형적인 상용간질폐렴 소견을 보일 때 조직학적 폐 생검 없이 진단 가능하다. 영상 검사는 특발폐섬유증의 평가 및 진단에 중추적인 역할을 하며, 정확한 진단을 위하여 임상적, 영상의학적 및 병리학적 소견에 대한 다학제 검토의 중요성이 강조된다. 간질성폐이상(interstitial lung abnormality)은 우연히 발견된 영상의학적 이상 소견을 지칭하며, 간질성폐이상과 임상적으로 의미 있는 간질폐질환에 대한 구분은 적절한 임상 평가를 기반으로 이루어져야 한다. 저자들은 이번 종설을 통하여 특발폐섬유증 진단의 최신 지견 및 간질성폐이상에 대한 이해를 도움으로써 미만성 간질폐섬유증 환자의 정확한 진단과 치료 및 예후 증진에 도움이 되고자 한다.

Keywords

Acknowledgement

This research was supported by the Soonchunhyang University Research.

References

  1. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378:1949-1961  https://doi.org/10.1016/S0140-6736(11)60052-4
  2. Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005;172:488-493  https://doi.org/10.1164/rccm.200412-1756OC
  3. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304  https://doi.org/10.1164/ajrccm.165.2.ats01
  4. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-748  https://doi.org/10.1164/rccm.201308-1483ST
  5. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824  https://doi.org/10.1164/rccm.2009-040GL
  6. Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 2018;6:138-153  https://doi.org/10.1016/S2213-2600(17)30433-2
  7. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018;198:e44-e68  https://doi.org/10.1164/rccm.201807-1255ST
  8. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 2016;194:265-275  https://doi.org/10.1164/rccm.201604-0801CI
  9. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-816  https://doi.org/10.1164/rccm.200602-163OC
  10. Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 2015;46:1113-1130  https://doi.org/10.1183/13993003.02316-2014
  11. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006;27:136-142  https://doi.org/10.1183/09031936.06.00037005
  12. Tsukamoto K, Hayakawa H, Sato A, Chida K, Nakamura H, Miura K. Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax 2000;55:958-961  https://doi.org/10.1136/thorax.55.11.958
  13. Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013;309:2232-2239  https://doi.org/10.1001/jama.2013.5827
  14. Allen RJ, Porte J, Braybrooke R, Flores C, Fingerlin TE, Oldham JM, et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir Med 2017;5:869-880  https://doi.org/10.1016/S2213-2600(17)30387-9
  15. Johkoh T, Muller NL, Cartier Y, Kavanagh PV, Hartman TE, Akira M, et al. Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients. Radiology 1999;211:555-560  https://doi.org/10.1148/radiology.211.2.r99ma01555
  16. Knuppel L, Ishikawa Y, Aichler M, Heinzelmann K, Hatz R, Behr J, et al. A novel antifibrotic mechanism of nintedanib and pirfenidone. Inhibition of collagen fibril assembly. Am J Respir Cell Mol Biol 2017;57:77-90  https://doi.org/10.1165/rcmb.2016-0217OC
  17. Hilberg O, Simonsen U, du Bois R, Bendstrup E. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. Clin Respir J 2012;6:131-143  https://doi.org/10.1111/j.1752-699X.2012.00302.x
  18. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-2082  https://doi.org/10.1056/NEJMoa1402584
  19. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-2092  https://doi.org/10.1056/NEJMoa1402582
  20. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192:e3-e19  https://doi.org/10.1164/rccm.201506-1063ST
  21. Raghu G, Wells AU, Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F, et al. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med 2017;195:78-85  https://doi.org/10.1164/rccm.201602-0402OC
  22. Johkoh T, Sakai F, Noma S, Akira M, Fujimoto K, Watadani T, et al. Honeycombing on CT; its definition, pathologic correlation, and future direction of its diagnosis. Eur J Radiol 2014;83:27-31  https://doi.org/10.1016/j.ejrad.2013.05.012
  23. Chung JH, Chawla A, Peljto AL, Cool CD, Groshong SD, Talbert JL, et al. CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis. Chest 2015;147:450-459  https://doi.org/10.1378/chest.14-0976
  24. Sumikawa H, Johkoh T, Colby TV, Ichikado K, Suga M, Taniguchi H, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 2008;177:433-439  https://doi.org/10.1164/rccm.200611-1696OC
  25. Edey AJ, Devaraj AA, Barker RP, Nicholson AG, Wells AU, Hansell DM. Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality. Eur Radiol 2011;21:1586-1593  https://doi.org/10.1007/s00330-011-2098-2
  26. Akira M, Kozuka T, Yamamoto S, Sakatani M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;178:372-378  https://doi.org/10.1164/rccm.200709-1365OC
  27. Gruden JF, Panse PM, Leslie KO, Tazelaar HD, Colby TV. UIP diagnosed at surgical lung biopsy, 2000-2009: HRCT patterns and proposed classification system. AJR Am J Roentgenol 2013;200:W458-W467  https://doi.org/10.2214/AJR.12.9437
  28. Tcherakian C, Cottin V, Brillet PY, Freynet O, Naggara N, Carton Z, et al. Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax 2011;66:226-231  https://doi.org/10.1136/thx.2010.137190
  29. Hunninghake GW, Zimmerman MB, Schwartz DA, King TE Jr, Lynch J, Hegele R, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;164:193-196  https://doi.org/10.1164/ajrccm.164.2.2101090
  30. Egashira R, Jacob J, Kokosi MA, Brun AL, Rice A, Nicholson AG, et al. Diffuse pulmonary ossification in fibrosing interstitial lung diseases: prevalence and associations. Radiology 2017;284:255-263  https://doi.org/10.1148/radiol.2017152419
  31. Chua F, Desai SR, Nicholson AG, Devaraj A, Renzoni E, Rice A, et al. Pleuroparenchymal fibroelastosis. A review of clinical, radiological, and pathological characteristics. Ann Am Thorac Soc 2019;16:1351-1359  https://doi.org/10.1513/AnnalsATS.201902-181CME
  32. Reddy TL, Tominaga M, Hansell DM, von der Thusen J, Rassl D, Parfrey H, et al. Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes. Eur Respir J 2012;40:377-385  https://doi.org/10.1183/09031936.00165111
  33. Brownell R, Moua T, Henry TS, Elicker BM, White D, Vittinghoff E, et al. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax 2017;72:424-429  https://doi.org/10.1136/thoraxjnl-2016-209671
  34. Yagihashi K, Huckleberry J, Colby TV, Tazelaar HD, Zach J, Sundaram B, et al. Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia. Eur Respir J 2016;47:1189-1197  https://doi.org/10.1183/13993003.01680-2015
  35. Sverzellati N, Wells AU, Tomassetti S, Desai SR, Copley SJ, Aziz ZA, et al. Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin-section CT diagnoses. Radiology 2010;254:957-964  https://doi.org/10.1148/radiol.0990898
  36. Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, et al. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med 2020;8:726-737  https://doi.org/10.1016/S2213-2600(20)30168-5
  37. Chae KJ, Jin GY, Goo JM, Chung MJ. Interstitial lung abnormalities: what radiologists should know. Korean J Radiol 2021;22:454-463  https://doi.org/10.3348/kjr.2020.0191
  38. Putman RK, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M, et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA 2016;315:672-681  https://doi.org/10.1001/jama.2016.0518
  39. Jin GY, Lynch D, Chawla A, Garg K, Tammemagi MC, Sahin H, et al. Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. Radiology 2013;268:563-571  https://doi.org/10.1148/radiol.13120816
  40. Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011;364:897-906  https://doi.org/10.1056/NEJMoa1007285
  41. Hatabu H, Hunninghake GM, Lynch DA. Interstitial lung abnormality: recognition and perspectives. Radiology 2019;291:1-3  https://doi.org/10.1148/radiol.2018181684
  42. Araki T, Putman RK, Hatabu H, Gao W, Dupuis J, Latourelle JC, et al. Development and progression of interstitial lung abnormalities in the Framingham Heart Study. Am J Respir Crit Care Med 2016;194:1514-1522  https://doi.org/10.1164/rccm.201512-2523OC
  43. Hunninghake GM, Hatabu H, Okajima Y, Gao W, Dupuis J, Latourelle JC, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med 2013;368:2192-2200  https://doi.org/10.1056/NEJMoa1216076
  44. Putman RK, Gudmundsson G, Axelsson GT, Hida T, Honda O, Araki T, et al. Imaging patterns are associated with interstitial lung abnormality progression and mortality. Am J Respir Crit Care Med 2019;200:175-183  https://doi.org/10.1164/rccm.201809-1652OC
  45. Rice MB, Li W, Schwartz J, Di Q, Kloog I, Koutrakis P, et al. Ambient air pollution exposure and risk and progression of interstitial lung abnormalities: the Framingham Heart Study. Thorax 2019;74:1063-1069  https://doi.org/10.1136/thoraxjnl-2018-212877
  46. Sack CS, Doney BC, Podolanczuk AJ, Hooper LG, Seixas NS, Hoffman EA, et al. Occupational exposures and subclinical interstitial lung disease. The MESA (multi-ethnic study of atherosclerosis) air and lung studies. Am J Respir Crit Care Med 2017;196:1031-1039  https://doi.org/10.1164/rccm.201612-2431OC
  47. Iwasawa T, Okudela K, Takemura T, Fukuda T, Matsushita S, Baba T, et al. Computer-aided quantification of pulmonary fibrosis in patients with lung cancer: relationship to disease-free survival. Radiology 2019;292:489-498  https://doi.org/10.1148/radiol.2019182466
  48. Araki T, Dahlberg SE, Hida T, Lydon CA, Rabin MS, Hatabu H, et al. Interstitial lung abnormality in stage IV non-small cell lung cancer: a validation study for the association with poor clinical outcome. Eur J Radiol Open 2019;6:128-131  https://doi.org/10.1016/j.ejro.2019.03.003
  49. Liu Y, Zhu Y, Wu R, Hu M, Zhang L, Lin Q, et al. Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease. Transl Lung Cancer Res 2020;9:2328-2336  https://doi.org/10.21037/tlcr-20-1050
  50. Li F, Zhou Z, Wu A, Cai Y, Wu H, Chen M, et al. Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy. Radiat Oncol 2018;13:82